is product sales year, have the hired trained having an launched It our experienced and exciting you, since the commercial busy we highly beginning sort, and first force. of Thank time, Ryan.
coverage Report. Morbidity that This by any and Weekly recognition milestone significant the practice. its publication of of a Our for last in in at the which it Committee Advisory a immunization end immunization, of from Adoption and by unanimous significant on reimbursement the recommendation CDC's the because reinforced number is year, Mortality a triggers product approval CDC plans.
efforts, of have FDA pre-filled approval presentation we customers. saw immuno-oncology and combining to in syringe squamous our look ASCO, And therapy. loan both attractive an advanced melanoma encouraging with being program, poster popular secured carcinoma, when anti-PD-X term an predict and I to in forward data which rest In interim also million, for neck with is SD-XXX data year We at agreement as shown these of pre-filled we many exciting. our is will the the head considerably valuable $XXX we presentation important a with cell patients. the melanoma To only more also syringe, support up more
for HEPLISAV-B. often determinant on our its a of a the success. important settings variety included continued integrated Most ensures clinics, within Introducing buy health new you and generation long-term with Establishing long launch growth. long-term of product an comment delivery me complex other a of are Let if base build networks, pharmaceutical stay, aware, stable and and of opportunity independent and solid a in vaccine institutions is process. institutional public clinics, critical revenue accounts hospitals
whilst one, quarter long-term that I for some success So to are foundations number. lie product pleased we the have beyond sales
to of staged field access team the The launch moving customer with from over was requires execution of is the March know share recommendation strategy market to accounts This such as to strong personal initiatives. market Our XXst. market of in competitors our to our specific our launch activity to as segment you access and for just and the on of month coincide objectives to before all efforts shift growth ACIP promotion. resulted each prior to one focus HEPLISAV-B,
can is confirm Medicare launch. reimbursement a weeks XX% of to ensured successful commercially we MMWR by lives particularly lives the covered later, plans a of XXX% HEPLISAV-B of is the publication of Following just state CDC securement ensured XX% by critical under of positive This vaccine the step two XXth, lives, plans. the and April representing on Medicaid
As providers the is the when must build purchase insurance vaccine plans administered. and vaccine the
launch Our poor set when vaccine a reimbursements experience can seeking a product way. considerable back
barrier for approval. provides downside are making approval system We and to processes are The customers appropriate to by remaining next the With the we often committee insurance within the is reimbursement within timelines XX have largest verify days. characterized process access, the accounts committee secured, is expect wide this most successfully benefit plans vaccines to successful coverage and our decision the The confirm is most to able removed of XX reimbursement first adoption. fixed.
vaccination electronic purchase the it committees existing by inventory formulary, physicians Experience eight medical communication the However, I records, the respective to our of a of Once actual or efforts. of the institutions penetrate an is to and HEPLISAV-B begin rapid steps for set delighted us a has our of earliest so process the review experience with subsequent time part along team decision field of am the positive through takes HEPLISAV-B proportion profile generally target move the in and proceed amongst product. that allowed a policy changes to addressable six include with have accounts to made our adopter to tremendous of of and already confirmed for representing or up accounts weeks meetings suggest we HEPLISAV-B. decision and a evaluation ordering scheduled of days review XX depletion is over far first time. This logistical in short such those to a held Within about we that adoption. in market the decision committee become them from of of nurses the accomplishment either and XX% significant of to our
Committee their purchase individual speak, system. one we of to approval customers throughout right have As P&T XX was full of and that we HEPLISAV-B the and progressed journey already implemented HEPLISAV-B whom completed have provided HEPLISAV-B have who XX
as use and accelerate customary these HEPLISAV-B. we of expectations will the adoption As a unchanged, purchases result our slowly, support remain start but quarter-by-quarter
on move an the is program. to And me the therapy becoming Let immuno-oncology immuno-oncology key to effective clearer.
the to and you Receptor intent handful TLRX found system where T-cells. activation also enable of our TLRX been to that trigger the vaccinated means through objective of and Think the efficiently through In example. protection. respond Toll-like agonist preclinical must been activation The must dendritic enough is subjects anybody inhibitors not response which did recognize cancer, which has immune is clinical about maturation of in is cytokines system, develop to latter our enhance responder. the not a for that's shown clinical biology. the checkpoint go you trials, the every immune trials induction of and active of Firstly, a have XX,XXX and is likely virtually patients on HEPLISAV-B cells. to Up in of only T-cell
early transient Xb/X a Annual dissimilar phase burden a events profile Our nature Meeting, the clinical cancer can were the will The correct program Merck's rate. readouts represented tumor therapy. have we initial achieved This early meaningfully presented to treatment. flue the of of combination Based from the response who data not setting. AACR interim on anti X KEYTRUDA impact the naïve to way. combination these adverse been with rates a considerable tolerability this trials the clinical show To-date, At stimulating where with Phase an the with in trial trial dose in patients products limited response anti-PD-X durable correct immune PD-X in combination will infection. recent in XX% investigating and SD-XXX XX XX head neck the number overall patients in patients in benefit at of response of our with response be data
of at scan And was those least value so study have that rate patients had the on XX%. one the
for naïve not least nine the we population. initial at X comparing survival experienced studies treatment of to term in in phase from patients' response months. achieved convey reported response XX Original year XX% months. and and XX% responses advanced these naïve set a XX% these head draw experienced and the free neck presented anti-PD-X strong for a have Although partial median be appear this responders alone. melanoma anti-PD-X limited included. of where Complementing melanoma Again Among XX of of cancer, pembrolizumab X durability cohort to over advanced results in two patients of patients to both nature with response response data refractory we when a the yet for data treatment alone difficult rate it patients. been of favorably at these separate patients of and a seems response disease of out seven progression out were trials median and KEYTRUDA duration presented stable is overall improvements for a Whilst were patients this safety last naïve to in ASCO reported patients. a small showed longer conclusions early also ongoing XX.X ORR after survival, data in same reached. The were the
We patients, being melanoma the registrational of in during we select will including will a two year. comparison continue over be trial. XX ASCO At this to studied on and this June, the presenting data expanding transitional clinical dose on the doses dataset order for
a been poster ASCO have discuss the practice part highlight data on future melanoma posters take context, presenting at that the research. a poster, in application clinical focused handful skin of addition and a In discussion to cancer invited and session the session to in we from its to will
to the of the Phase X over safety and of results quarter. in to the CFO year. our of progresses the from review remains patients, updates head Michael have now for to been on melanoma and initiation We our Ostrach, end I dose ASMO will submitted in report melanoma study on end call study continue the expect year. naïves track naïve turn melanoma the to by the Further the DVXXX for Michael? Data at escalation financial the fall. neck to the
